psoriasis
PSORIASIS

Psoriasis is a systemic chronic skin disorder characterized by excessive keratinocytes proliferation that results into thickened scaly plaques, itching and inflammatory changes in the epidermis and dermis. It is transmitted genetically but can be provoked by environmental factors.
It is found in approximately 2% of the population that primarily affects the skin and joints.
It is associated with other inflammatory disorders and autoimmune diseases (eg psoriatic arthritis, inflammatory bowel disease, coronary artery disease).
Generally, it begins as red scaling papules that coalesce to form round-to-oval plaques. The rashes are often pruritic and may be painful.

  1. Alefacept (Amevive) for treatment of psoriasis. Med Lett Drugs Ther. 2003 Apr;45(1154):31-32. PMID: 12717339
  2. Ashcroft DM, Li Wan Po A, Williams HC, et al. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ. 2000 Apr;320(7240):963-967. PMID: 10753146
  3. Efalizumab (Raptiva) for treatment of psoriasis. Med Lett Drugs Ther. 2003 Dec;45(1171):97-98. PMID: 14657802
  4. Cohen SN, Baron SE, Archer CB; British Association of Dermatologists and Royal College of General Practitioners. Guidance on the diagnosis and clinical management of psoriasis. Clin Exp Dermatol. 2012 May;37(Suppl 1):13-18. doi: 10.1111/j.1365-2230.2012.04337.x. PMID: 22486764
  5. Drew GS. Psoriasis. Prim Care. 2000 Jun;27(2):385-406. PMID: 10815050
  6. Federman DG, Froelich CW, Kirsner RS. Topical psoriasis therapy. Am Fam Physician. 1999 Feb;59(4):957-962, 964. PMID: 10068717
  7. Kollner K, Wimmershoff MB, Hintz C, et al. Comparison of the 308-nm excimer laser and a 308-nm excimer lamp with 311- nm narrowband ultraviolet B in the treatment of psoriasis. Br J Dermatol. 2005 Apr;152(4):750-754. PMID: 15840108
  8. Koo J, Lee E, Lee CS, et al. Psoriasis. J Am Acad Dermatol. 2004 Apr;50(4):613-622. PMID: 15034513
  9. Ladizinski B, Lee KC, Wilmer E, Alavi A, et al. A review of the clinical variants and the management of psoriasis. Adv Skin Wound Care. 2013 Jun;26(6):271-284. doi: 10.1097/01.ASW.0000429778.10020.67. PMID: 23669329
  10. Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol. 2001 Oct;45(4):487-498. PMID: 11568737
  11. Lebwohl M, Menter A, Koo J, et al. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol. 2004 Mar;50(3):416-430. PMID: 14988684
  12. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol. 2001 Nov;45(5):649-661. PMID: 11606913
  13. Lebwolhl M. Advances in psoriasis therapy. Dermatol Clin. 2000 Jan;18(1):13-19. PMID: 10626107
  14. Luba KM, Stulberg DL. Chronic plaque psoriasis. Am Fam Physician. 2006 Feb;73(4):636-644. PMID: 16506705
  15. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009 Apr;60(4):643-659. doi: 10.1016/j.jaad.2008.12.032. PMID: 19217694
  16. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. Jun 03, 2009. J Am Acad Dermatol. 2009 Sep;61(3):451-485. http://www.ncbi.nlm.nih.gov/pubmed/?term=19493586. PMID: 19493586
  17. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008 May;58(5):826-850. http://www.ncbi.nlm.nih.gov/pubmed/?term=18423260. PMID: 18423260
  18. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. Feb 08, 2011. J Am Acad Dermatol. 2011 Jul;65(1):137-174. http://www.ncbi.nlm.nih.gov/pubmed/?term=21306785. PMID: 21306785
  19. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010 Jan;62(1):114-135. doi: 10.1016/j.jaad.2009.08.026. PMID: 19811850
  20. Mudigonda T, Dabade TS, West CE, Feldman SR. Therapeutic modalities for localized psoriasis: 308-nm UVB excimer laser versus nontargeted phototherapy. Cutis. 2012 Sep;90(3):149-154. PMID: 23094316
  21. Ortonne JP, Humbert P, Nicolas JP, et al. Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 mcg g -1 ointment and calcipotriol 50 mcg g -1 ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Br J Dermatol. 2003 Feb;148(2):326-333. PMID: 12588387
  22. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol. 2005 Sep;153(3):486-497. PMID: 16120132
  23. Pardasani AG, Feldman SR, Clark AR. Treatment of psoriasis: an algorithm-based approach for primary care physicians. Am Fam Physician. 2000 Feb;61(3):725-733, 736. PMID: 10695585
  24. Zeichner JA, Lebwohl MG, Menter A, et al. Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis. 2010 Sep;86(3 Suppl):5-31. PMID: 21049712
  25. Trehan M, Taylor CR. Medium-dose 308-nm excimer laser for the treatment of psoriasis. J Am Acad Dermatol. 2002 Nov;47(5):701-708. PMID: 12399761
  26. Habif TP. Psoriasis and other papulosquamous diseases. Clinical dermatology: a color guide to diagnosis and therapy. 5th ed. Pennsylvania: Mosby, Elsevier; 2010
  27. MedWormhttp://www.medworm.com/rss/index.php/Allergy-%26-Immunology/3/http://www.medworm.com/rss/medicalfeeds/specialities/Allergy-Immunology.xml
  28. MedWormhttp://www.medworm.com/rss/index.php/Dermatology/12/http://www.medworm.com/rss/medicalfeeds/specialities/Dermatology.xml
  29. MedWormhttp://www.medworm.com/rss/index.php/Pediatrics/33/http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics.xml
  30. Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis: overview. http://www.torontodermatologycentre.com. Aug 2011. Accessed 19 Jul 2013.
  31. National Institute for Health and Care Excellence. Adalimumab for the treatment of adults with psoriasis. NICE. http://www.nice.org.uk. Jun 2008
  32. Persatuan Dermatologi Malaysia (Dermatological Society of Malaysia). Consensus Statement: the management of psoriasis. http://www.acadmed.org.my/view_file.cfm?fileid=228. 1996
  33. Scottish Intercollegiate Guidelines Network. Diagnosis and management of psoriasis and psoriatic arthritis in adults. SIGN. http://www.sign.ac.uk. 2010.
  34. National Institute for Health and Care Excellence. Etanercept and efalizumab for the treatment of adults with psoriasis. NICE. http://www.nice.org.uk. Jul 2006
  35. Feldman SR. Epidemiology, pathophysiology, clinical manifestations, and diagnosis of psoriasis. UpToDate. http://www.uptodate.com/index. Dec 2010. Accessed 25 Apr 2011.
  36. British Association of Dermatologists. Psoriasis guideline. http://www.bad.org.uk. 2006. Accessed 07 Nov 2006.
  37. National Institute for Health and Care Excellence. Infliximab for the treatment of adults with psoriasis. NICE. http://www.nice.org.uk. Jan 2008
  38. National Institute for Health and Care Excellence. Psoriasis: the assessment and management of psoriasis. NICE. http://www.nice.org.uk. Oct 2012.
  39. National Psoriasis Foundation. Psoriasis severity. http://www.psoriasis.org. 2013. Accessed 19 Jul 2013.
  40. National Institute for Health and Care Excellence. Ustekinumab for the treatment of adults with moderate to severe psoriasis. NICE. http://www.nice.org.uk. Sep 2009
  41. Novartis Pharmaceuticals Corporation. Cosentyx (secukinumab): highlights of prescribing information. http://www.pharma. us.novartis.com/product/pi/pdf/cosentyx.pdf. Jan 2015.
  42. US Food and Drug Administration. FDA approves new psoriasis drug Cosentyx. http://www.fda.gov/newsevents/newsroom/ pressannouncements/ucm430969.htm. 21 Jan 2015.
  43. Ministry of Health Malaysia, Dermatological Society of Malaysia, Academy of Medicine Malaysia. Clinical practice guidelines. Management of psoriasis vulgaris. Academy of Medicine Malaysia. http://www.acadmed.org.my/index.cfm?&menuid=67#Skin_Condition. Jun 2013.
  44. Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2277-2294. doi: 10.1111/jdv.13354. PMID: 26481193
  45. Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017 May 17. doi: 10.1111/bjd.15665. PMID: 28513835
  46. American Academy of Dermatology Work Group, Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011 Jul;65(1):137-174. doi: 10.1016/j.jaad.2010.11.055. PMID: 21306785
  47. Feldman SR. Treatment of psoriasis in adults. UptoDate. http://www.uptodate.com/. Nov 2017.
  48. Nast A, Spuls PI, van der Kraaij G, et al. European S3-Guideline on the systemic treatment of psoriasis vulgaris – Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2017 Dec;31(12):1951-1963. doi: 10.1111/jdv.14454. PMID: 28895202
  49. National Institute for Health and Clinical Excellence (NICE). Apremilast for treating moderate to severe plaque of psoriasis. NICE. https://www.nice.org.uk/. Nov 2016.
  50. Weigle N, McBane S. Psoriasis. Am Fam Physician. 2013 May;87(9):626-633. https://www.aafp.org/. PMID: 23668525
  51. Feldman SR. Epidemiology, clinical manifestations, and diagnosis of psoriasis. UpToDate. http://www.uptodate.com. Jul 2017.
  52. Nast A, Boehncke WH, Mrowietz U, et al. S3 - Guidelines on the treatment of psoriasis vulgaris (english version). update. J Dtsch Dermatol Ges. 2012 Mar;10(Suppl 2):S1-S95. doi: 10.1111/j.1610-0387.2012.07919.x. PMID: 22386073
  53. Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019 Apr;80(4):1073-1113. doi: 10.1016/j.jaad.2018.11.058. PMID: 30773097
  54. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. PMID: 30772098
  55. National Institute for Health and Care Excellence (NICE). Dimethyl fumarate for treating moderate to severe plaque psoriasis. NICE. http://www.nice.org.uk. Sep 2017.
Editor's Recommendations
Most Read Articles
28 May 2019
Trifarotene is safe, well-tolerated and effective in treating both facial and truncal acne, according to two phase III trials.
26 Mar 2019
Sunscreen products commonly contain only filters against ultraviolet (UV) radiation. At a recentdinner symposium organized by Eucerin, Dr Rungsima Wanitphakdeedecha discussed whythis is insufficient and what is required for effective protection against the damaging effects ofsunlight on the skin
28 Apr 2019
Women who adopt healthy diets appear to have less severe facial wrinkles, according to a new Dutch study.
01 Sep 2018

QV Intensive with Ceramides
Ego Pharm Malaysia Sdn Bhd